Vmbook Online ordering

Icons

**Company Information**

**Name:** Johnson & Johnson

**Stock Symbol:** JNJ

**Exchange:** New York Stock Exchange (NYSE)

**Industry:** Healthcare

**Headquarters:** New Brunswick, New Jersey, USA

**Bandaid Product Line**

Bandaid is a brand of adhesive bandages owned by Johnson & Johnson. It is one of the most recognized and trusted brands in the wound care category.

**Financial Performance**

**Earnings:**

* Johnson & Johnson reported revenue of $93.8 billion in 2022, a 6.8% increase from the previous year.

* Net income for 2022 was $20.7 billion, a 2.1% increase from 2021.

**Growth:**

* Johnson & Johnson has consistently delivered steady growth over the past several years.

* The company's revenue has grown at a compound annual growth rate (CAGR) of approximately 5% over the past 5 years.

* Net income has also grown at a CAGR of approximately 4% over the same period.

**Key Metrics:**

* **Price-to-Earnings (P/E) Ratio:** 25.8

* **Price-to-Sales (P/S) Ratio:** 4.9

* **Dividend Yield:** 2.6%

* **Market Capitalization:** $450 billion (as of February 2023)

**Analyst Ratings:**

* The majority of analysts covering Johnson & Johnson have a "Buy" or "Overweight" rating on the stock.

* The consensus price target for JNJ is $180, representing a potential upside of approximately 10% from current levels.

**Outlook**

Johnson & Johnson has a strong track record of financial performance and is well-positioned for continued growth in the future. The company's diverse portfolio of healthcare products and services provides it with a competitive advantage.

The Bandaid brand is a key part of Johnson & Johnson's wound care business, which is expected to continue growing in the coming years. Increasing demand for wound care products, particularly in emerging markets, is driving growth for the industry.